Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Cancer Related Cognitive Decline × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 31 Breast Neoplasms 23 Prostatic Neoplasms 20 Stomach Neoplasms 13 Squamous Cell Carcinoma of Head and Neck 11 Neoplasms 10 Triple Negative Breast Neoplasms 9 Lung Neoplasms 9 Urinary Bladder Neoplasms 7 Head and Neck Neoplasms 7 Neoplasm Metastasis 6 Nasopharyngeal Carcinoma 5 Carcinoma, Squamous Cell 5 Adenocarcinoma 5 Non-Muscle Invasive Bladder Neoplasms 4 Carcinoma, Transitional Cell 4 Sarcoma 3 Recurrence 3 Prostatic Neoplasms, Castration-Resistant 3 Ovarian Neoplasms 3 Oropharyngeal Neoplasms 3 HER2-positive Breast Cancer 3 Endometrial Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Advanced Solid Tumors 3 Vaccinia 2 Salivary Gland Neoplasms 2 Peritoneal Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Metastatic Castration-resistant Prostate Cancer 2

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡